Azenta, Inc. Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2024. Financial statements are unaudited and presented under U.S. GAAP. Azenta provides sample management, multiomics, genomic, automated storage, and temperature-controlled storage and transport solutions for life sciences customers. Effective October 1, 2023, the Company realigned reporting into Sample Management Solutions, Multiomics, and B Medical Systems.
Key Financial Metrics
| Metric | Three months ended Mar. 31, 2024 | Three months ended Mar. 31, 2023 | Six months ended Mar. 31, 2024 | Six months ended Mar. 31, 2023 |
|---|---|---|---|---|
| Revenue | $159.1 million | $148.4 million | $313.5 million | $326.8 million |
| Gross profit | $63.4 million | $53.2 million | $124.9 million | $127.1 million |
| Gross margin | 39.8% | 35.9% | 39.8% | 38.9% |
| Operating loss | $(147.0) million | $(13.0) million | $(173.6) million | $(40.7) million |
| Net loss | $(136.9) million | $(4.9) million | $(152.6) million | $(16.2) million |
| Diluted loss per share | $(2.47) | $(0.07) | $(2.72) | $(0.23) |
| Operating cash flow | Not separately provided | Not separately provided | $34.8 million | $(39.2) million |
- Revenue mix: Second-quarter revenue was $74.1 million from Sample Management Solutions, $62.2 million from Multiomics, and $22.8 million from B Medical Systems. Six-month revenue was $153.1 million, $124.9 million, and $35.4 million, respectively.
- Adjusted profitability: Management reported second-quarter adjusted operating loss of $5.7 million, or a 3.6% adjusted operating margin, compared with a $13.3 million loss and 8.9% negative margin in the prior-year quarter. Six-month adjusted operating loss was $14.4 million, or a 4.6% negative margin, compared with $13.3 million and 4.1% negative margin in the prior-year period.
- Cash and liquidity: Cash and cash equivalents were $353.5 million at March 31, 2024. Including restricted cash and marketable securities, liquidity totaled $975.4 million, compared with $1.134 billion at September 30, 2023. Management stated that available liquidity should fund operating expenses and capital requirements for at least one year and the foreseeable future.
- Debt: The Company reported no outstanding debt on its balance sheet. Operating lease liabilities totaled $74.2 million, including $10.8 million current and $63.4 million long term.
- Investments: Marketable securities totaled $611.2 million at March 31, 2024, primarily U.S. government-backed and corporate debt securities. Unrealized losses were $2.5 million.
- Share repurchases: Azenta repurchased 3.5 million shares for $186.8 million during the six months ended March 31, 2024. Since inception of the authorization, 20.9 million shares had been repurchased for $1.025 billion, leaving $475 million authorized.
Material Changes Versus Prior Comparable Period
- Second-quarter revenue increased 7.2%, driven by a 50.6% increase in B Medical Systems and a 4.4% increase in Sample Management Solutions; Multiomics revenue was essentially flat.
- Six-month revenue declined 4.1%, primarily because B Medical Systems revenue fell 37.9% due to the timing of cold-chain equipment orders. Sample Management Solutions increased 4.5% and Multiomics increased 1.3%.
- Gross margin improved to 39.8% from 35.9% in the second quarter and to 39.8% from 38.9% for the six-month period, reflecting margin expansion across the businesses in the quarter and stronger Sample Management Solutions and Multiomics margins year to date.
- Operating expenses increased substantially because of a $111.3 million non-cash goodwill impairment charge for B Medical Systems, a $4.7 million impairment of intangible assets related to the discontinued sample sourcing offering, and higher restructuring charges. The prior-year period benefited from a $17.1 million contingent-consideration fair-value gain that did not recur.
- Operating cash flow improved to $34.8 million from an outflow of $39.2 million, while investing cash flow was $(172.2) million and financing cash flow was $(187.2) million, primarily due to marketable-security purchases and share repurchases.
Outlook, Unusual Items, and Risks
- Impairment: The B Medical Systems reporting unit recorded a $111.3 million goodwill impairment after lower anticipated revenue growth and changed economic conditions reduced estimated fair value. Further impairment charges could result if performance, macroeconomic conditions, or valuation assumptions deteriorate.
- Transformation and restructuring: The Company launched initiatives covering facility consolidation, portfolio optimization, and organizational simplification, with activities expected to continue through fiscal 2026. It recorded $7.3 million of second-quarter restructuring charges and $8.5 million for the six-month period; additional actions and charges may be identified in future periods.
- B Medical performance: Although second-quarter revenue and margins improved because of order timing and product mix, six-month revenue and adjusted operating results deteriorated materially. Management identified order delays and lower cold-chain sales volume as key factors.
- Leadership transition: On May 8, 2024, President and CEO Stephen Schwartz announced his intention to retire after a successor is appointed. The filing identifies the transition, retention of key personnel, and potential shareholder activism as risks.
- Contingencies: A $1.7 million accrued liability remains for an unresolved indemnification claim by Edwards Vacuum. The Company also accrued $3.2 million for estimated tariffs related to historical imports, subject to U.S. customs review.
- Commitments: Non-cancellable commitments totaled $52.0 million, including $47.9 million for inventory purchases and $4.1 million for information technology.
- Guidance: The filing does not provide a clear quantitative revenue or earnings outlook. Management expects liquidity to remain sufficient and is focused on profitability, cost reduction, and transformation initiatives.
- Other risks: Key risks include demand and order timing, macroeconomic conditions, foreign-exchange exposure, supply-chain and customer concentration risks, goodwill valuation, cybersecurity, international operations, tax matters, and execution of the transformation program.
Investor Verification Priorities
- Verify whether B Medical Systems revenue recovery and profitability improvements persist beyond the quarter and whether additional impairment is required.
- Track the timing, scope, and cash costs of the transformation and restructuring program through fiscal 2026.
- Reconcile adjusted operating results to GAAP results and assess the recurring nature of excluded costs.
- Monitor cash deployment, remaining share-repurchase authorization, and the decline in total liquidity from September 30, 2023.
- Follow the CEO succession process and potential effects on strategy, retention, and shareholder activism.
- Review the Edwards indemnification claim, tariff exposure, tax valuation allowances, and other legal or regulatory contingencies.